Immunopathogenesis of hepatic flare in HIV/hepatitis b virus (Hbv)-coinfected individuals after the initiation of Hbv-active antiretroviral therapy

Background. The pathogenesis of and risk factors for hepatic flare (HF) after the initiation of hepatitis B virus (HBV)-active antiretroviral therapy (ART) in HIV/HBV-coinfected individuals is not well understood. Methods. We studied HF in ART-naive HIV/HBV-coinfected individuals in Thailand (n= 36)...

Full description

Bibliographic Details
Main Authors: Crane, M., Oliver, B., Matthews, G., Avihingsanon, A., Ubolyam, S., Markovska, V., Chang, J., Dore, G., Price, Patricia, Visvanathan, K., French, M., Ruxrungtham, K., Lewin, S.
Format: Journal Article
Published: Oxford University Press 2009
Online Access:http://hdl.handle.net/20.500.11937/27864
_version_ 1848752382074159104
author Crane, M.
Oliver, B.
Matthews, G.
Avihingsanon, A.
Ubolyam, S.
Markovska, V.
Chang, J.
Dore, G.
Price, Patricia
Visvanathan, K.
French, M.
Ruxrungtham, K.
Lewin, S.
author_facet Crane, M.
Oliver, B.
Matthews, G.
Avihingsanon, A.
Ubolyam, S.
Markovska, V.
Chang, J.
Dore, G.
Price, Patricia
Visvanathan, K.
French, M.
Ruxrungtham, K.
Lewin, S.
author_sort Crane, M.
building Curtin Institutional Repository
collection Online Access
description Background. The pathogenesis of and risk factors for hepatic flare (HF) after the initiation of hepatitis B virus (HBV)-active antiretroviral therapy (ART) in HIV/HBV-coinfected individuals is not well understood. Methods. We studied HF in ART-naive HIV/HBV-coinfected individuals in Thailand (n= 36) who were beginning HBV-active ART as part of a prospective clinical trial. HF was defined as an alanine aminotransferase (ALT) level-5 times the upper limit of normal or-200 IU/L higher than that at baseline. Immune mediators (interleukin [IL]-18, IL-2, IL-6, IL-8, IL-10, soluble CD26 [sCD26], sCD30, sCD8, CXCL-10, CCL-2, tumor necrosis factor-a, interferon [IFN]-?, and IFN-a) and activated NK cells were quantified. Results. HBV DNA and ALT levels at baseline were higher in patients with HF (n-8) than in patients without HF (n = 28) (P < .01). After the initiation of ART, CXCL-10 levels remained elevated in patients with HF but decreased in patients without HF (P = .01). sCD30 levels increased and were significantly higher at week 8 in patients with HF (P < .05). There was a positive correlation between levels of ALT and levels of CXCL-10, sCD30, CCL-2, and IL-18 at week 8 (the time of peak ALT level) but not at other time points. Conclusion. Elevated HBV DNA and ALT levels before the initiation of HBV-active ART are risk factors for HF. The pathogenesis of HF after the initiation of HBV-active ART is probably consistent with immune restoration disease. © 2009 by the Infectious Diseases Society of America.
first_indexed 2025-11-14T08:07:44Z
format Journal Article
id curtin-20.500.11937-27864
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T08:07:44Z
publishDate 2009
publisher Oxford University Press
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-278642017-09-13T15:13:26Z Immunopathogenesis of hepatic flare in HIV/hepatitis b virus (Hbv)-coinfected individuals after the initiation of Hbv-active antiretroviral therapy Crane, M. Oliver, B. Matthews, G. Avihingsanon, A. Ubolyam, S. Markovska, V. Chang, J. Dore, G. Price, Patricia Visvanathan, K. French, M. Ruxrungtham, K. Lewin, S. Background. The pathogenesis of and risk factors for hepatic flare (HF) after the initiation of hepatitis B virus (HBV)-active antiretroviral therapy (ART) in HIV/HBV-coinfected individuals is not well understood. Methods. We studied HF in ART-naive HIV/HBV-coinfected individuals in Thailand (n= 36) who were beginning HBV-active ART as part of a prospective clinical trial. HF was defined as an alanine aminotransferase (ALT) level-5 times the upper limit of normal or-200 IU/L higher than that at baseline. Immune mediators (interleukin [IL]-18, IL-2, IL-6, IL-8, IL-10, soluble CD26 [sCD26], sCD30, sCD8, CXCL-10, CCL-2, tumor necrosis factor-a, interferon [IFN]-?, and IFN-a) and activated NK cells were quantified. Results. HBV DNA and ALT levels at baseline were higher in patients with HF (n-8) than in patients without HF (n = 28) (P < .01). After the initiation of ART, CXCL-10 levels remained elevated in patients with HF but decreased in patients without HF (P = .01). sCD30 levels increased and were significantly higher at week 8 in patients with HF (P < .05). There was a positive correlation between levels of ALT and levels of CXCL-10, sCD30, CCL-2, and IL-18 at week 8 (the time of peak ALT level) but not at other time points. Conclusion. Elevated HBV DNA and ALT levels before the initiation of HBV-active ART are risk factors for HF. The pathogenesis of HF after the initiation of HBV-active ART is probably consistent with immune restoration disease. © 2009 by the Infectious Diseases Society of America. 2009 Journal Article http://hdl.handle.net/20.500.11937/27864 10.1086/597276 Oxford University Press unknown
spellingShingle Crane, M.
Oliver, B.
Matthews, G.
Avihingsanon, A.
Ubolyam, S.
Markovska, V.
Chang, J.
Dore, G.
Price, Patricia
Visvanathan, K.
French, M.
Ruxrungtham, K.
Lewin, S.
Immunopathogenesis of hepatic flare in HIV/hepatitis b virus (Hbv)-coinfected individuals after the initiation of Hbv-active antiretroviral therapy
title Immunopathogenesis of hepatic flare in HIV/hepatitis b virus (Hbv)-coinfected individuals after the initiation of Hbv-active antiretroviral therapy
title_full Immunopathogenesis of hepatic flare in HIV/hepatitis b virus (Hbv)-coinfected individuals after the initiation of Hbv-active antiretroviral therapy
title_fullStr Immunopathogenesis of hepatic flare in HIV/hepatitis b virus (Hbv)-coinfected individuals after the initiation of Hbv-active antiretroviral therapy
title_full_unstemmed Immunopathogenesis of hepatic flare in HIV/hepatitis b virus (Hbv)-coinfected individuals after the initiation of Hbv-active antiretroviral therapy
title_short Immunopathogenesis of hepatic flare in HIV/hepatitis b virus (Hbv)-coinfected individuals after the initiation of Hbv-active antiretroviral therapy
title_sort immunopathogenesis of hepatic flare in hiv/hepatitis b virus (hbv)-coinfected individuals after the initiation of hbv-active antiretroviral therapy
url http://hdl.handle.net/20.500.11937/27864